Afamitresgene Autoleucel & Vorasidenib
from OncoPharm Hosted by John Bossaer
A new cellular therapy is approved for synovial sarcoma and the anticipated approval has occurred for the dual IDH1/IDH2 inhibitor, vorasidenib.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 12 minutes long.
When was this OncoPharm episode published?
This episode was published on August 8, 2024.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.